This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.
Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
Commercial Support
This activity is supported by an independent educational grant from Bristol Myers Squibb.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Global Learning Collaborative (GLC) has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.
Faculty:
James Cleary, MD, PhD
Senior Oncologist
Dana-Farber Cancer Institute
Boston, MA
Contracted Researcher: Amgen, Arcus Biosciences, Bristol Myers Squibb, GSK, Merck, Merus, Pyxis, Servier
Advisor/Consultant: Abdera, BeOne, Gilead, Prelude
Reviewers/Content Planners/Authors:- Tim Person has no relevant relationships to disclose.
- Jocelyn Timko has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP has no relevant relationships to disclose.
- Tim Person has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Evaluate the impact of molecular biomarkers on treatment selection and decision-making in metastatic gastrointestinal/gastroesophageal junction cancers
- Increase clinical knowledge and data confidence in recent trials and their implications for the first-line management of advanced HER2-negative upper gastrointestinal cancers
- Formulate first-line treatment selection strategies for patients with advanced HER2-negative upper gastrointestinal cancers, incorporating guideline recommendations and approved and emerging therapies
- Evaluate the impact of molecular biomarkers on treatment selection and decision-making in metastatic gastrointestinal/gastroesophageal junction cancers
Target Audience
This activity has been designed to meet the educational needs of oncologists and gastroenterologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with upper GI cancers.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.Global Learning Collaborative (GLC) designates this activity for 0.50 contact hour(s)/0.05 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is UAN JA0006235-0000-25-119-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit(s). Approval is valid until 09/30/2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date: